“Both these designations together give rise to an expectation that FDA is likely to be flexible, recognises the unmet need that this product can fill and will likely work with the company to get this product to the market as fast as possible.” My belief is , the above statement will short cut many of the time frames being quoted currently for CHF with LVADs, .....
Ann: FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs, page-58
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.030(2.73%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.05 | $28.73M | 25.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14264 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24626 | 3 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
-0.030 ( 2.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.05 | 5190842 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |